Synchron vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synchron pioneers the world's first endovascular BCI (Stentrode) enabling paralysis patients to control devices with thoughts; raised $200M Series D (Nov 2025) totaling $345M, Apple BCI-HID integration achieved.
About
Synchron is a neurotechnology company developing brain-computer interface (BCI) technology using a minimally invasive endovascular surgical approach. Unlike conventional BCIs that require open-brain surgery to implant electrode arrays directly on the cortex, Synchron's Stentrode device is delivered through a catheter inserted via the jugular vein and positioned in a blood vessel adjacent to the motor cortex — requiring no open neurosurgery and dramatically reducing patient risk and recovery time. The Stentrode detects neural signals associated with intended movement and translates them into digital commands, enabling individuals with severe paralysis — from ALS, stroke, or spinal cord injury — to control computers, smartphones, and other devices using thought alone.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.